Fleming JA~Blackman RK, 2002

Pubmed ID 11830665
Title Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341.
Authors James A Fleming, Eric S Lightcap, Seth Sadis, Vala Thoroddsen, Christine E Bulawa, Ronald K Blackman
Abstract Although the biochemical targets of most drugs are known, the biological consequences of their actions are typically less well understood. In this study, we have used two whole-genome technologies in Saccharomyces cerevisiae to determine the cellular impact of the proteasome inhibitor PS-341. By combining population genomics, the screening of a comprehensive panel of bar-coded mutant strains, and transcript profiling, we have identified the genes and pathways most affected by proteasome inhibition. Many of these function in regulated protein degradation or a subset of mitotic activities. In addition, we identified Rpn4p as the transcription factor most responsible for the cell's ability to compensate for proteasome inhibition. Used together, these complementary technologies provide a general and powerful means to elucidate the cellular ramifications of drug treatment.
Citation Proc. Natl. Acad. Sci. U.S.A. 2002; 99:1461-6

Datasets

Download the list of datasets
Papers Phenotype Conditions Collection Tested mutants Data Details
Fleming JA~Blackman RK, 2002 growth (relative abundance in pooled culture) Ps-341 [260 uM] hom 4,277 Quantitative only for hits
Fleming JA~Blackman RK, 2002 growth (relative abundance in pooled culture) PS-519 [8 uM] hom 4,277 Quantitative only for hits

Curation history

Data

July 6, 2016 Data to request.
July 6, 2016 Data requested.
July 18, 2016 Data loaded.

Tested strains

July 6, 2016 Tested strains to request.
July 6, 2016 Tested strains requested.
July 18, 2016 Tested strains loaded.